PRESS RELEASE

25 April 2014

ABT: Update on Restorsea complaint

Aqua Bio Technology ASA (Oslo Axess: ABT) today provided an update on the complaint filed with a New York court by ABT's customer and exclusivity partner Restorsea.

The court has scheduled a conference with the parties' legal counsel on 7 May 2014 for a preview of ABT's request for dismissal of Restorsea's complaint. No court decision is expected in this conference. As previously noted, Aqua Bio Technology's position is that the complaint is substantively and procedurally deficient, and the Company has submitted a request for dismissal.

After learning of the complaint, further dialogue between the parties has been initiated, in an effort to reach a solution outside the court. ABT has recently met with Restorsea, and has provided the exclusivity partner with additional technical documentation. ABT's intention is to clarify and resolve potential misunderstandings.

The legal process moves forward in parallel with the dialogue between the parties.

ABT will update the market in accordance with its obligations as a company listed on the Oslo Stock Exchange.

For further information, please call Arvid Lindberg, CEO, telephone +47 9824 5410

Aqua Bio Technology ASA (ABT) develops, produces and markets patented ingredients and technologies to the international cosmetic and skin care industry. ABT's ingredients Aquabeautine XL™, Dermaclarine™ and Beauty Propelline™ are marine solutions with distinctly individual and unique properties, derived from the hatching fluid of salmon. ABT is listed on the Oslo Stock Exchange's Axess market.

.